

Maja **Banjin**, MD

Professor of Oncology, Sarajevo **School of Science and Technology**

Head of Department of Medical Oncology , Oncology Clinic, Clinical Center of Sarajevo University (KCU Sarajevo)

Phone +387 61 701 844

E-mail address: banjinmaja@yahoo.com

1. RESEARCH INTEREST (3-4 sentences total)

Malignant diseases of the digestive system; malignant skin diseases; neuroendocrine carcinomas; systemic oncology treatments (chemotherapy, immunotherapy and target therapy); palliative care.

2. EDUCATION (Faculty, Doctorate)

- 2015** Obtained PhD in Medical Science at University of Sarajevo, Medical Faculty (KCU Sarajevo) ; PhD Doctoral thesis under title “ Prognostic and predictive value of immunohistochemical determination of epidermal growth factor receptors and neangiogenesis in gastric and esophagogastric carcinoma” under mentorship of Prof. Elmir Čičkušić, MD PhD, University of Tuzla, Medical Faculty.
- 2009** Obtained Master's Degree in Medical Science at University of Sarajevo, Medical Faculty (KCU Sarajevo) ; MSc, thesis,, Prognostic and predictive significance of neovascularization in colon cancer” under mentorship of Prof. Nermina Obralić, MD PhD, University of Sarajevo, Medical Faculty.
- 2007** Passed final examination in Medical Oncology at KCU Sarajevo and became MD sub-specialist in Medical Oncology .
- 1999** Passed final examination in Internal Medicine at KCU Sarajevo and became MD specialist in internal medicine.
- 1986** Passed GP general examination in the Republic Ministry of the Health, Work and Social Welfare in Sarajevo and received the title MD.
- 1985** Graduated at University of Sarajevo, Medical Faculty and obtained Bachelor's Degree in Medicine.

3. WORK EXPERIENCE

- 1985-present** University Clinical Center Sarajevo, Oncology Clinic
- 2014-present** **Position:** Head of Department of Medical Oncology. **Responsibilities:** Management and organization of oncologic therapy in hospital and in out-patients units of the Department of Medical Oncology.
- 2007-ongoing** **Position:** Subspecialist in medical oncology. **Responsibilities:** malignant disease of digestive tract, skin cancer and neuroendocrine carcinoma.

- 1999-2007** **Position:** Specialist in internal medicine. **Responsibilities:** providing out-patients with systemic oncology therapy.
- 1993-1999** **Position:** Resident in internal medicine.
- 1986-1993** **Position:** General Practitioner. **Responsibilities:** in charge of symptomatic therapy of oncological patients within the framework of the „Clinical at home“ project.

4. TEACHING EXPERIENCE

- 1999-2008** Teacher of Internal Medicine at the Medical School of the Catholic School of Education in Sarajevo
- 2010-2015** Assistant lecturer of Oncology , Farmaceutical-Health Faculty, Travnik University
- 2015-2017** Assistant professor of Oncology, Farmaceutical-Health Faculty, Travnik University.
- 2015–present** Assistant professor of Palliative Care, School of Medicine , University of Sarajevo
- 2018-present** Professor of Oncology at Sarajevo **School of Science and Technology.**

5. PROFESSIONAL DEVELOPMENT

Main training courses:

- 1998 Regional education course in genetics and oncology in Dubrovnik, Croatia.
- 1999 Mediterranean School of Oncology, Alexandria, Egypt.
- 2000 Writing, reading and randomizing clinical trials, The Postgraduate Course organized by ESMO (European Society for Medical Oncology) in Wien, Austria
- 2001 Immunology research in the field of malignant melanoma in The Clinical Center, Ljubljana, Slovenia.
- 2001 Education in bone marrow transplantation in The Regional hospital, Ravenna, Italy
- 2002 Training in conducting scientific research in undefined statuses in oncology in the Scientific-research department of the Regional medical center, Florence, Italy
- 2002 Obtained GRP Certificate in recognition of successful completion of The School of Good Clinical Practice and for demonstrating effective application of the principles therein
- 2003 ESMO Annual oncology school in Tenerife, Spain

2004 The first educational course on neuroendocrine tumors in Bled, Slovenia.
2005 ESMO Annual oncology school in Tenerife, Spain

6. FUNDED PROJECTS

1998 Phase III Study of Gemcytabine/Epirubycine/Paclitaxel combinations vs. Standard-Fluorouracil/Epiruibicin/Cyclophosphamide Combination as First line chemotherapy in Metastatic breast Cancer- CECOG, Lilly.

2000 Multicenter Phase III Randomized trial comparing Docetaxel with Doxorubicin and Cyclophosphamide versus Doxorubicin and Cyclophosphamide followed by Docetaxel as adjuvant treatment of operable breast cancer HER2 negative patients with positive axillary lymph nodes, BCIRG 005

2005 Open-label Trial of Gleevec with unresectable or Metastatic malignant GIST c-Kit expressing, CECOG/Clinical phase of Trial IV

2005 First line bevacizumab and chemotherapy in metastatic cancer of the Colon and Rectum – Bevacizumab expanded access trial / Clinical phase of Trial IV

2005 Randomized, clinical study phase II: Folfox 6 + cetuximab compared with FOLFIRI + cetuximab, as the first line therapy with metastatic colorectal carcinoma- cECOG study.

2007 A Multicenter Multinational Phase 3 Randomized Study to Evaluate the Safety and Efficacy of Treating Colorectal Cancer Patients with Recurrent Liver Metastases using Lixiv System plus Chemotherapy as Compared to Chemotherapy Alone.

2008 A Multicenter Multinational Phase 2 Randomized Study to Evaluate the Safety and Efficacy of Treating gastric cancer patients with PEPO2 vs. Irinotecan vs. Docetaxel as 2nd line therapy.

2012 An open-label, multicenter expanded access study of RO5185426 in patients with metastatic melanoma.

2013- A Multicenter Multinational Phase 3: Evaluated the Safety and Efficacy of Treating metastatic BCC Patients with Vismodegib

7. PUBLICATIONS

a) Original scientific papers

1. Kapiđić A; Banjin S, and **Banjin-Čardžić M**. Metastatic lymphomas in malignant thyroid tumors. SYMPOSIUM ON TUMOR RESEARCH IN ORL, 4. Abstracts; Dusseldorf. Dusseldorf: s.n.; 1991:12.

2. Bešlija S; Mušanović M; Bašić H; Tatarević A, and **Banjin M**. Docetaxel (Taxotere) as the first line therapy in women with metastatic breast cancer: A single institution study. CONGRESS OF RADIOLOGY OF B&H, 1st- 100 YEARS OF RADIOLOGY IN SARAJEVO. Book of Abstract; Sarajevo. Sarajevo: Association of radiology of Medical Association of B&H; 1999: 203 (97).

3. Bešlija S; Paraganlija N; Bašić H; Kazić N, and **Banjin M**. A phase II trial of 5-Fluorouracil and leucovorin in patients with metastatic colorectal cancer. CONGRESS OF RADIOLOGY OF B&H, 1ST -100 YEARS OF RADIOLOGY IN SARAJEVO. Book of Abstract; Sarajevo: Association of Radiology of Medical Association of B&H; 1999: 206 (100).

4. **Banjin M** and Čardžić A. Maligni tumori tankog crijeva. U. ONKOLOGIJA. Sarajevo: Bošnjački institut, Fondacija Adil Zulfikarpašić; 2001; pp. 279-80.

5. **Banjin M**; Obralić N; Bešlija S; Parganlija N, and Bašić H. Xeloda in treatment of the colorectal carcinoma. MED ARH. 2002; 56(1, Supl.1):71.

Notes: 1. Kongres gastroenterologa I hepatologa Bosne I Hercegovine sa medjunarodnim učešćem, Sarajevo, maj 2002.

6. Obralić N; Gribajčević M; Bešlić Š; Paraganlija N; **Banjin M**, and Tatarević- Šuko A. Indicators in frequency of digestive tract tumors in register of malignanat neoplasm of the Clinical Centre of Sarajevo University. MED ARH. 2002; 56(1, Supl.1):80.

7. Osmić H; Obralić N; **Banjin M**; Paraganlija N; Dragnić E, and Dalibegović A. Chemotherapy of advanced pancreatic carcinoma. MED ARH. 2002; 56(1, Supl.1):77.

Notes: 1. Kongres gastroenterologa I hepatologa Bosne I Hercegovine sa medjunarodnim učešćem, Sarajevo, Maj 2002.

8. Paraganlija N; Obralić N; **Banjin M**; Bešlija S; Bešlić S. Adjuvanth chemotherapy and radiation rectum cacrcinoma stage II and III. MED ARH. 2002; 56(1, Supl.1):70.

9. Šošević A; Obralić N; Bešlija S, and **Banjin M**. Malignant insulinoma-oncological treatment. MED ARH. 2002; 56(1, Supl.1):77.

Notes: 1. Kongres gastroenterologa I hepatologa Bosne I Hercegovine sa medjunarodnim učešćem, Sarajevo, Maj 2002.

10. Bešlija S; Obralić N; Bašić H; Tatarević A; Mahić N; **Banjin M**; Šošević A; Cerić T; Pašić A and Salkić B. A single institution randomized trial of taxotere (T) and Xeloda (X) given in combined vs. taxotere(T) followed by Xeloda(X) for metastatic breast cancer(MBC). EJC SUPPL. 2005; 3(2):114-114.

11. Pasic A, Cerić T, Beslija S, **Banjin M**, Salkić B, Sosevic A. Internet technology and multidisciplinary approach to cancer patients at Institute of oncology Sarajevo ESO Conference on Managing cancer service 2005 Milan , Italy

12. Salkić B, **Banjin M**, Sosevic A, Pasic A, Cerić T, Beslija S. Time to progression in patients with metastatic CRC treated with irinotecan or capecitabine as first line treatment (retrospective study). ESEC(ESMO Scientific & Educational Conference) 2005 Budapest Hungary

13. Beslija S, Obralic N, Basic H, Tatarevic A, Mahic N, **Banjin M**, Cardzic A, Sosevic A, Pasic A, Cerić T, Salkić B. A Single Institution Randomized Trial of Taxotere (T) and Xeloda (X) Given in

Combination vs. Taxotere (T) followed by Xeloda (X) after progression as First Line Chemotherapy (CT) for Metastatic Breast Cancer (MBC). EJC suppl.2005; 3(2):114-114.

14. Bešlija S; Obralić N; Bašić H; Tatarević A; Mahić N; **Banjin M**; Čardžić A; Šošević A; Cerić T; Pašić A and Salkić B. Randomized trial of sequence vs. combination of capecitabine (X) and docetaxel (T): XT vs. T followed by X after progression as first-line therapy for patients (pts) with metastatic breast cancer (MBC). J CLIN ONCOL. 2006; 24(18, Part 1 Suppl.):20S-20S.

15. Vesnić S; Đurović V; Lincender L; **Banjin M**; Sefić I; Civić H, and Avdagić E. Intraarterijska aplikacija citostatika u tretmanu hepatocelularnog carcinoma. Kongres hirurga/kirurgia Federacije Bosne i Hercegovine sa međunarodnim učešćem, 1. Zbornik sažetaka; First Congress of Surgery of Federation of Bosnia and Herzegovina with international participation; Sarajevo. Sarajevo: Institut za naučnoistraživački rad i razvoj KCUS; 2006: 93-94.

16. S. Beslija, N. Obralic, H. Basic, A. Tatarevic, M. Naila, **M. Banjin**, A. Cardzic, A. Sosevic, A. Pasic, T. Ceric and B. Salkic. Randomized trial of sequence vs. combination of capecitabine (X) and docetaxel (T): XT vs. T followed by X after progression as first-line therapy for patients (pts) with metastatic breast cancer (MBC). Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings. Vol 24, No 18S, 2006: 571.

17. S. Beslija, **M. Banjin**, S. Jungic, N. Obralic, G. Kecman-Malcic, I. Rakita, B. Salkic, A. Pasic, L. Tinjic and V. Smoljanovic. Preliminary phase II study results of capecitabine (X) + irinotecan (I) + bevacizumab (A) as first-line therapy for patients (pts) with metastatic colorectal cancer (MCRC). Journal of Clinical oncology, 2007 ASCO Annual Meeting(Post meeting Edition). Vol 25, No 18S, 2007: 1452.

18. S. Bešlija, **M. Banjin**, S. Jungic, N. Obralic, G. Kecman-Malcic, I. Rakita, B. Salkic, A. Pasic, L. Tinjic and V. Smoljanovic. Update phase II study results of capecitabine (X) + irinotecan (I) + bevacizumab (A) as first-line therapy for metastatic colorectal cancer (MCRC). J Clin Oncol, 2009 ASCO Annual Meeting, Vol 27, No 15S, 2009: e15064

19. **Banjin-Cardzic M**, Obralic N, Bilalović N, Beslija S, Tinjic L, Smoljanovic V. Predictive and prognostic importance of neovascularization in colorectal carcinoma. Ann Oncol 2010; 21(suppl 6): 72-73.

20. **Banjin M**. Bilalović N, Obralić N, Lincender L. Prediktivni i prognostički značaj neovaskularizacije u kolorektalnom karcinomu. Medicinski žurnal 2011; 17(3): 202-209.

21. **Banjin M**. Adjuvantna terapija kolorektalnog karcinoma, Kolorektalni karcinom danas. Akademija nauka i umjetnosti Bosne i Hercegovine Knjiga apstrakta 2011;

22. L. Lincender, **M. Banjin**, D. Vrcić, S. Gornjaković, v. Đurović Sarajlić, S. Vegar- Zubović, S. Prevljak. Procjena MR holangiopankreatografije u komparaciji sa US/EUS i ERCP u dijagnostici malignih bilijarnih bolesti. Medicinski žurnal 2011; 17(2): 108-112.

23. L. Lincender-Cvijetić, **M. Banjin- Čardžić**. S. Vegar-Zubović. D. Vrcić. Radiological imaging of rectal cancer. Acta Medica Academica 2012;41(2):199-209.

24. **Banjin M**. Adjuvantna i neoadjuvantna sistemska onkološka terapija. First Sarajevo colon cancer expert meeting Knjiga apstrakta 2012;

25. A. Sofić, Š. Bešlić, A. Husić-Selimović, A. Đuran, Đ. Eminagić, B. Gogov, **M. Banjin**. CTC and MRI assesment of local tumor staging of rectal carcinoma. Medicinski žurnal 2013;19(3): 212-218.
26. A.C.Roy, S.R.Park, D.Cunningham, Z.K.Kang, Y.Chao, L.T.Chen, C.Rees, H.Y.Lim, J.Taberner, F.J.Ramos, M. Kujundzic, **M.Banjin Cardic**, C.G.Yeh and A.de Gramont. A randomized phase II study of PEP02 (MM-398), irinotecan or docetaxel as a second-line therapy in patients with locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma. Ann Oncol 00: 1-7, 2013.
27. A.Pašić, S. Bešlija, **M. Banjin**. P-189 Correlation between of expression of the enzyme topoisomerase I and p53 and result of irinotecan based therapy in patients with metastatic colorectal cancer. Annals of Oncology 2015;26(4): iv55-iv55
28. Bešlija S, Vrbanc D. Medicinska/internistička onkologija, Medicinski fakultet Univerziteta u Sarajevu 2014
- M. Banjin**. Karcinom jednjaka. Medicinska/internistička onkologija: 114-123.
- M. Banjin**. Karcinom želuca. Medicinska/internistička onkologija Medicinski fakultet Univerziteta u Sarajevu 2014: 123-131.
- M.Banjin**. Maligni tumori tankih crijeva. Medicinska/internistička onkologija Medicinski fakultet Univerziteta u Sarajevu 2014: 131-139.
- M. Banjin**. Karcinom kolona i rektuma. Medicinska/internistička onkologija Medicinski fakultet Univerziteta u Sarajevu 2014: 139-163.
- M. Banjin**. Analni karcinom. Medicinska/internistička onkologija Medicinski fakultet Univerziteta u Sarajevu 2014: 163-167.
29. A. Sofić, Š. Bešlić, **M. Banjin** . Magnetic resonance imaging to evaluate neoadjuvant therapy effects on rectal carcinoma. Acta Clinica Croatica 2015; 54(3): 303-307.
30. Pasic, S. Beslija, A. Djuran, I. Sefic-Pasic, **M. Banjin**, T. Ceric, A. Rasic, B. Hasanbegovic, A. Jalovcic, E. Kapisazovic. Correlation between of expression of the enzyme topoisomerase I and p53 and result of irinotecan based therapy in patients with metastatic colorectal cancer. Annals of Oncology 26 (Supplement 4): iv1–iv100, 2015.
31. L. Kandolf Sekulović, **M. Banjin** . More than 5000 patients with metastatic melanoma in Europe per year do not have access to recommended first-line innovative treatments. European Journal of Cancer 2017; 75: 313-322.
32. **M. Banjin**. Ciljana terapija I metastatski melanom. Akademija nauka i umjetnosti Bosne I Hercegovine Knjiga apstrakta 2018;
33. **M.Banjin**. Melanom, Udruženje onkologa u BiH 2018

b) Conferences, presentations, abstracts, proceedings

- | | |
|---------------|---|
| November 1998 | The XIV European Society of Medical Oncology in Athens, Greece. |
| November 2000 | The XV European Society of Medical Oncology in Hamburg, Germany |
| October, 2001 | XVI ESMO Lisbon, Portugal |
| May, 2002 | ASCO, Orlando, USA |

October, 2003	XII European Cancer Conference organized by FECS (Federation of European Cancer Societies) in Copenhagen, Denmark
June, 2004	ESMO Gastro-intestinal carcinoma congress, Barcelona, Spain
June, 2005	ESMO Gastro-intestinal carcinoma congress, Barcelona, Spain
June, 2006	ESMO Gastro-intestinal carcinoma congress, Barcelona, Spain
October 2006	31th ESMO in Istanbul, Turkey
February 2008	International Congress on Anti-Cancer Treatment, Paris, France
June 2009	ESMO Gastro-intestinal carcinoma congress, Barcelona, Spain
October 2009	34 th ESMO in Berlin, Germany
March 2010	ENETS, Berlin, Germany
June 2010	ASCO, Chicago
June, 2010	ESMO Gastro-intestinal carcinoma congress, Barcelona, Spain
October,2010	35 th ESMO Congress, Milan Italy
June, 2011	ESMO Gastro-intestinal carcinoma congress, Barcelona, Spain
March, 2012	MSD Oncology Melanoma Forum , Amsterdam, The Netherlands
June, 2012	ESMO Gastro-intestinal carcinoma congress, Barcelona, Spain
November 2012	Expert Forum on Biosimilarity, Istanbul, Turkey
June, 2014	ESMO Gastro-intestinal carcinoma congress, Barcelona, Spain
June, 2016	ESMO Gastro-intestinal carcinoma congress, Barcelona, Spain
October, 2017	ESMO Congress, Madrid, Spain
June, 2018	ESMO Gastro-intestinal carcinoma congress, Barcelona, Spain
October, 2018	ESMO Congress, Munich, Germany